Loading…
Ligand Pharmaceuticals Incorporated is projected to rise to $357.30 by 2027, a +51% move from its current price of $235.89. LGND is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $230.84 | $236.08 | $241.43 | +0.08% |
| May 30 | $228.89 | $236.26 | $243.87 | +0.16% |
| May 31 | $227.44 | $236.45 | $245.81 | +0.24% |
| Jun 1 | $226.26 | $236.63 | $247.48 | +0.31% |
| Jun 2 | $225.24 | $236.82 | $248.99 | +0.39% |
| Jun 3 | $224.34 | $237.01 | $250.38 | +0.47% |
| Jun 4 | $223.53 | $237.19 | $251.68 | +0.55% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $223.53 | $237.19 | $251.68 | +0.55% |
| Week 2 | $219.31 | $238.50 | $259.37 | +1.11% |
| Week 3 | $216.41 | $239.82 | $265.76 | +1.66% |
| Week 4 | $214.17 | $241.14 | $271.50 | +2.23% |
| Week 5 | $212.36 | $242.47 | $276.85 | +2.79% |
| Week 6 | $210.84 | $243.81 | $281.93 | +3.36% |
| Week 7 | $209.56 | $245.15 | $286.80 | +3.93% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that develops and licenses biopharmaceutical assets worldwide. It operates in the Healthcare sector and maintains a broad portfolio, including Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin A nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, TZIELD, VAXNEUVANCE; Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis.
Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Ligand Pharmaceuticals Incorporated (LGND) is a healthcare stock with current price $229.33 and market cap $4.6B, ranked 1398. The stock shows a bullish technical bias based on current metrics.
A major floor 23.0% below — a decisive break under it would weaken the trend.
The nearest floor, 11.9% below — buyers have tended to step in here.
Price is pressing into resistance (2.5% away) — a breakout level to watch.
A major ceiling 11.3% above — clearing it would confirm fresh momentum.
Key LGND support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LGND market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $228.10 | Buy | $229.16 | Buy |
| MA 10 | $220.96 | Buy | $225.09 | Buy |
| MA 20 | $222.94 | Buy | $223.12 | Buy |
| MA 50 | $217.29 | Buy | $217.76 | Buy |
| MA 100 | $206.99 | Buy | $208.82 | Buy |
| MA 200 | $194.30 | Buy | $191.29 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.20 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 125.01 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 1.33 | Buy |
| ROC (12) | 6.54 | Buy |
| Bollinger %B (20,2) | 0.89 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.05 | Buy |
| Awesome (5,34) | 4.14 | Buy |
| Ultimate (7,14,28) | 70.60 | Sell |
| Momentum (10) | 13.89 | Buy |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 237.10 | Sell |
| ADX (14) | 14.13 | Neutral |
| ATR (14) | 4.76 | Info |
The 30-day technical picture shows bullish sentiment with RSI14 at 60, SMA50 at $216.08, and SMA200 at $193.43. The stock sits on support at $207.78 and faces resistance at $241.79.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $181.65 | $235.89 | $344.55 | 0% | Neutral | |
| $288.30 | $357.30 | $466.02 | +51% | Bullish | |
| $346.04 | $438.32 | $589.15 | +86% | Bullish | |
| $371.63 | $479.39 | $659.94 | +103% | Bullish | |
| $419.37 | $549.74 | $772.32 | +133% | Bullish | |
| $486.52 | $647.15 | $925.56 | +174% | Bullish | |
| $603.89 | $814.27 | $1,183.47 | +245% | Bullish | |
| $719.14 | $982.09 | $1,448.43 | +316% | Bullish | |
| $765.95 | $1,058.72 | $1,582.69 | +349% | Bullish | |
| $830.43 | $1,161.13 | $1,757.77 | +392% | Bullish | |
| $1,430.54 | $2,106.65 | $3,363.14 | +793% | Bullish | |
| $2,649.27 | $4,258.27 | $7,351.99 | +17.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $181.65 | $235.89 | $276.50 | +0.00% |
| June 2026 | $206.14 | $241.16 | $288.11 | +2.23% |
| July 2026 | $215.15 | $253.42 | $306.16 | +5.09% |
| August 2026 | $218.78 | $259.09 | $315.70 | +2.24% |
| September 2026 | $217.40 | $258.60 | $317.31 | -0.19% |
| October 2026 | $222.21 | $265.40 | $327.72 | +2.63% |
| November 2026 | $229.06 | $274.57 | $340.93 | +3.46% |
| December 2026 | $229.50 | $276.04 | $344.55 | +0.54% |
Click any year to see its month-by-month LGND forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Ligand Pharmaceuticals Incorporated's 2026 outlook centres on $235.89, within a $181.65 to $344.55 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, LGND could reach as high as $466.02, with a base case around $357.30 and support toward $288.30 — roughly +51% from $235.89. Buyers look set to stay in control over this stretch.
Expect LGND to range from $346.04 to $589.15 through 2028. The $438.32 average target implies a +86% move from current prices. That is up +23% on the projected 2027 average. Momentum favours further upside here.
The LGND price prediction for 2029 points to an average of $479.39 (low $371.63, high $659.94) — a potential gain of +103% on today's $235.89. Buyers look set to stay in control over this stretch.
In 2030, LGND is projected to trade between $419.37 and $772.32, averaging $549.74 — a potential gain of +133% from today's $235.89. That is up +15% on the projected 2029 average. Momentum favours further upside here.
Ligand Pharmaceuticals Incorporated's 2031 outlook centres on $647.15, within a $486.52 to $925.56 range. That is up +18% on the projected 2030 average. That marks a +174% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, LGND could reach as high as $1,183.47, with a base case around $814.27 and support toward $603.89 — roughly +245% from $235.89. Momentum favours further upside here.
Expect LGND to range from $719.14 to $1,448.43 through 2033. The $982.09 average target implies a +316% move from current prices. That is up +21% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The LGND price prediction for 2034 points to an average of $1,058.72 (low $765.95, high $1,582.69) — a potential gain of +349% on today's $235.89. Momentum favours further upside here.
In 2035, LGND is projected to trade between $830.43 and $1,757.77, averaging $1,161.13 — a potential gain of +392% from today's $235.89. That is up +10% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Ligand Pharmaceuticals Incorporated's 2040 outlook centres on $2,106.65, within a $1,430.54 to $3,363.14 range. That is up +81% on the projected 2035 average. That marks a +793% change versus current levels. Momentum favours further upside here.
By 2050, LGND could reach as high as $7,351.99, with a base case around $4,258.27 and support toward $2,649.27 — roughly +17.1x from $235.89. Buyers look set to stay in control over this stretch.
Investing $1,000 in LGND today (≈ 4.239264 LGND) could be worth
$18,051.92
+$17,051.92 (+1705%) by 2050 · US Dollar
Based on the average projected LGND price of $4,258.27 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LGNDwould be worth at today's price.
$1,000 invested in LGND on May 27, 2025 (≈ 9.838646 LGND) would be worth
$2,320.84
+$1,320.84 (+132.1%) today · 2.32× · US Dollar
Based on a LGND entry price of $101.64 vs. today's $235.89.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $217.75 | $1,083.31 | +8.3% |
| 1 month ago | $241.79 | $975.6 | -2.4% |
| 3 months ago | $196.17 | $1,202.48 | +20.2% |
| 6 months ago | $203.18 | $1,160.99 | +16.1% |
| 1 year ago | $101.64 | $2,320.84 | +132.1% |
| All time (5.0y) ago | $70.85 | $3,329.5 | +233.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LGND forecast.
Our base-case forecast reaches $470.00 around 2029.
Implied market cap at $470.00: $9.42B
Multi-year forecasts point to a bullish trajectory after 2026. The 2026 forecast lists a min of $181.65, an average of $229.33, and a max of $336.72 with a neutral sentiment and 0% ROI. From 2027 onward, the outlook improves: 2027 min $282.17, avg $350.94, max $459.99 with 53% ROI and bullish sentiment; 2028 min $338.27, avg $430.38, max $581.87 with 87.7% ROI; 2029 min $358.80, avg $465.23, max $644.71 with 102.9% ROI; 2030 min $407.87, avg $537.81, max $761.06 with 134.5% ROI.
Further years show continued upside, including 2031 avg $635.21, 2032 avg $796.44, 2033 avg $967.72, 2034 avg $1,039.05, 2035 avg $1,133.41, 2040 avg $2,071.99, and 2050 avg $4,174.04 with corresponding max values and rising ROI up to 1720.1%. Overall, the long-term path remains bullish, though these are estimates and not guarantees.
Tap a question to reveal the answer.
In 2030 the forecast shows min $407.87, avg $537.81, max $761.06, with a 134.5% ROI and bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with rising averages (e.g., 2027 avg $350.94, 2028 avg $430.38, 2029 avg $465.23, 2030 avg $537.81) and positive ROI (53% in 2027, 134.5% in 2030). The 2026 forecast is neutral with an average of $229.33.
Yes. The forecast max for 2033 is $1,439.76, and the following years show max values of $1,567.55 in 2034 and $1,732.21 in 2035, indicating prices above $1000 are within the modeled path.
The 2026 forecast lists min $181.65, average $229.33, max $336.72, with neutral sentiment and 0% ROI.
Long-term projections show growing upside: 2040 average $2,071.99 and 2050 average $4,174.04, with max values of $3,344.53 and $7,302.11, respectively. The year 2030 is forecast to average $537.81, with a 134.5% ROI, and 2035 to average $1,133.41, with a 394.2% ROI.
Ligand Pharmaceuticals Incorporated Community Discussion
0Share your Ligand Pharmaceuticals Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.